FDA Grants Priority Review to Roche's Enspryng for MOGAD

The U.S. Food and Drug Administration granted Priority Review to Genentech/Roche's supplemental Biologics License Application for Enspryng (satralizumab), positioning the therapy for a potential decision by January 10, 2027. If cleared, the medication would become the first approved disease-modifying treatment for myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD), a rare central nervous system autoimmune condition that currently lacks any approved therapies.

"MOGAD can be unpredictable and debilitating, with each relapse carrying the potential for lasting neurological damage, yet there are currently no approved treatments," said Levi Garraway, M.D., Ph.D., chief medical officer and head of Global Product Development at Roche.

Clinical Trial Efficacy and Phase III METEOROID Results

The FDA accepted the application and granted an expedited review timeline based on data from the Phase III METEOROID clinical study according to a press release. The trial evaluated the efficacy of satralizumab against a placebo in preventing clinical relapses in patients diagnosed with MOGAD.

Key efficacy metrics from the study include:

• Relapse Risk Reduction: Enspryng demonstrated a 68% reduction in the risk of relapses compared to placebo (p=0.0025).
• Relapse-Free Rates: 87% of patients treated with Enspryng remained relapse-free at 48 weeks, compared to 67% in the placebo arm.

"Enspryng has the potential to transform care for people living with MOGAD, significantly reducing serious attacks and decreasing the reliance on high-dose steroids and immunosuppressants," Garraway said in a statement.

Understanding MOGAD and Current Treatment Challenges

MOGAD is a rare autoimmune inflammatory disorder characterized by immune system attacks against myelin oligodendrocyte glycoprotein, a protein on the surface of myelin sheath cells in the central nervous system. These attacks cause inflammation in the optic nerves, spinal cord, and brain, leading to symptoms such as vision loss, motor dysfunction, and paralysis.

Historically, clinicians have relied on off-label therapies such as chronic corticosteroids, intravenous immunoglobulins, and broad immunosuppressants to manage flares. These interventions often carry significant long-term toxicity profiles and fail to selectively target the underlying autoimmune mechanism, leaving patients vulnerable to cumulative neurological damage from subsequent attacks.

Regulatory Timelines in the United States and Europe

Under the FDA's Priority Review designation, the regulatory agency aims to take action on an application within six months, compared to the standard ten-month review window. This pathway is granted to therapies that offer significant improvements in the safety or effectiveness of the treatment, diagnosis, or prevention of serious conditions.

In addition to the U.S. review process, the European Medicines Agency has validated the marketing authorization application for Enspryng in MOGAD. A final decision from the European Commission is anticipated in the third quarter of 2027.